Cargando…

Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism

Platinum-based chemotherapeutic drugs are irreplaceable for the treatment of advanced non-small cell lung cancer (NSCLC). However, acquired drug resistance has become a major obstacle for the clinical application of chemotherapy on NSCLC. In the present study, we established carboplatin-resistant NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yong, He, Chunxi, Huang, Xianping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650413/ https://www.ncbi.nlm.nih.gov/pubmed/29088858 http://dx.doi.org/10.18632/oncotarget.20663

Ejemplares similares

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
por: Carter, Corey A., et al.
Publicado: (2016)

Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer
por: Marini, Cecilia, et al.
Publicado: (2013)

Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
por: Zang, Shuzhi, et al.
Publicado: (2019)

Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion
por: Kang, Joon Hee, et al.
Publicado: (2016)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Metformin inhibits high glucose-induced smooth muscle cell proliferation and migration
por: Zhou, Dong-Ming, et al.
Publicado: (2020)

Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT
por: Qi, Yuxin, et al.
Publicado: (2021)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas, Michael, et al.
Publicado: (2017)

Metformin and Cancer Glucose Metabolism: At the Bench or at the Bedside?
por: Marini, Cecilia, et al.
Publicado: (2021)

Partial Reversible Inhibition of Enzymes and Its Metabolic and Pharmaco-Toxicological Implications
por: Masson, Patrick, et al.
Publicado: (2023)

Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin
por: García-Puga, Mikel, et al.
Publicado: (2020)

SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling
por: Chen, Tai-yu, et al.
Publicado: (2022)

The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice
por: Zhou, Qiyun, et al.
Publicado: (2022)

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer
por: Litchfield, Lacey M., et al.
Publicado: (2015)

Perftoran( ® ) Inhibits Hypoxia-Associated Resistance in Lung Cancer Cells to Carboplatin
por: Gamal-Eldeen, Amira M., et al.
Publicado: (2022)

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
por: Zhang, Yiping, et al.
Publicado: (2018)

Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport
por: Horakova, Olga, et al.
Publicado: (2019)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
por: Sun, Hong, et al.
Publicado: (2022)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes
por: Meijer, Tineke W.H., et al.
Publicado: (2019)

Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer
por: Wahdan-Alaswad, RS, et al.
Publicado: (2018)

Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin
por: Xue, Chaojun, et al.
Publicado: (2016)

Let-7 underlies metformin-induced inhibition of hepatic glucose production
por: Xie, Di, et al.
Publicado: (2022)

Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7/ADR cells and xenograft models
por: Li, Ying, et al.
Publicado: (2017)

Combined metformin and insulin treatment reverses metabolically impaired omental adipogenesis and accumulation of 4-hydroxynonenal in obese diabetic patients
por: Jaganjac, Morana, et al.
Publicado: (2017)

3-Weekly Paclitaxel-Carboplatin With Radical Radiation for Stage III NSCLC – An Option During COVID-19 Pandemic
por: Wong, H.C.Y., et al.
Publicado: (2021)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

Pemetrexed induces ROS generation and cellular senescence by attenuating TS‐mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC
por: Chen, Yun, et al.
Publicado: (2023)

High Expression of PTGR1 Promotes NSCLC Cell Growth via Positive Regulation of Cyclin-Dependent Protein Kinase Complex
por: Huang, Xianping, et al.
Publicado: (2016)

NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin
por: Suwei, Dong, et al.
Publicado: (2015)

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
por: Li, Li, et al.
Publicado: (2016)

Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway
por: Zhang, Ye, et al.
Publicado: (2020)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sbl1u7aahe603d8na3nc3t1h86